Lalit Pai, CEO and Director of NKure Therapeutics

🌟 Showcasing #StartupSuccessStories — where India’s homegrown biotech innovators are transforming cancer treatment through innovative science and scalable solutions.

Meet Lalit Pai, CEO & Director of NKure Therapeutics, incubated at CCAMP_India.

Backed by @dbtindia - BIRAC support, NKure is pioneering off-the-shelf Natural Killer (NK) cell-based immunotherapy — an advanced, safe, and affordable alternative to conventional CAR-T therapies.

Unlike T-cell therapies that need pre-programming, NK cells are part of our innate immune system, naturally equipped to detect and eliminate stressed, infected, or cancerous cells.

NKure’s platform enhances these cells’ metabolic fitness, functionality, and persistence, offering long-term protection with minimal side effects such as GVHD or cytokine storms.

NKure is advancing to Phase I clinical trials, aiming to bring accessible, next-gen immunotherapies to India and beyond.

Backed by C-CAMP mentorship and DBT–BIRAC support, NKure Therapeutics is advancing #Immunotherapy — making next-gen #CellAndGeneTherapy safer, scalable, and affordable for all.

#BiotechInnovation #NKCells

Видео Lalit Pai, CEO and Director of NKure Therapeutics канала Department of Biotechnology